Search

Displaying results 3301 - 3310 of 6951 in total
  1. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

    Categories: Colony Stimulating Factor-1 Receptor Blocker
  2. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.

    Categories: Dopamine D2 Receptor Agonists
  3. Drug

    Ceftibuten

    go.drugbank.com/drugs/DB01415
    ApprovedInvestigational

    Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma

  5. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  6. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. … [L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose.

  7. Target

    Ribosome-binding protein 1

    go.drugbank.com/bio_entities/BE0003466
    TargetHumans

    Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane

    Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homolog
  8. Target

    Natural killer cells antigen CD94

    go.drugbank.com/bio_entities/BE0010559
    TargetHumans

    Immune receptor involved in self-nonself discrimination.

    Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activity
  9. Drug

    Chloroxylenol

    go.drugbank.com/drugs/DB11121
    Approved

    Chloroxylenol, or para-chloro-meta-xylenol (PCMX), is an antiseptic and disinfectant agent used for skin disinfection and surgical instruments.

  10. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    Dexamethasone was therefore recommended as a life-saving treatment for COVID-19 patients experiencing severe respiratory symptoms.[L14318] … [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions.